Go Pro

West Pharmaceutical Services (WST) Stock Price, News & Analysis

West Pharmaceutical Services logo
$328.61 -26.87 (-7.56%)
Closing price 07/24/2026 03:59 PM Eastern
Extended Trading
$328.28 -0.33 (-0.10%)
As of 07/24/2026 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About West Pharmaceutical Services Stock (NYSE:WST)

Advanced

Key Stats

Today's Range
$327.97
$351.79
50-Day Range
$304.31
$365.87
52-Week Range
$223.83
$386.00
Volume
1.51 million shs
Average Volume
741,347 shs
Market Capitalization
$23.22 billion
P/E Ratio
42.08
Dividend Yield
0.27%
Price Target
$363.17
Consensus Rating
Buy

Company Overview

West Pharmaceutical Services Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

WST MarketRank™: 

West Pharmaceutical Services scored higher than 77% of companies evaluated by MarketBeat, and ranked 340th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    West Pharmaceutical Services has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 11 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    West Pharmaceutical Services has a consensus price target of $363.17, representing about 10.5% upside from its current price of $328.61.

  • Amount of Analyst Coverage

    West Pharmaceutical Services has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about West Pharmaceutical Services' stock forecast and price target.
  • Earnings Growth

    Earnings for West Pharmaceutical Services are expected to grow by 9.63% in the coming year, from $8.93 to $9.79 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of West Pharmaceutical Services is 42.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of West Pharmaceutical Services is 42.08, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.

  • Price to Earnings Growth Ratio

    West Pharmaceutical Services has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    West Pharmaceutical Services has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.36% of the float of West Pharmaceutical Services has been sold short.
  • Short Interest Ratio / Days to Cover

    West Pharmaceutical Services has a short interest ratio ("days to cover") of 3.58, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in West Pharmaceutical Services has recently increased by 1.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    West Pharmaceutical Services has a dividend yield of 0.27%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    West Pharmaceutical Services does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of West Pharmaceutical Services is 11.27%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 8.99% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.

  • Read more about West Pharmaceutical Services' dividend.
  • News Sentiment

    West Pharmaceutical Services has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 37 news articles for West Pharmaceutical Services this week, compared to 6 articles on an average week.
  • Search Interest

    Only 5 people have searched for WST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added West Pharmaceutical Services to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, West Pharmaceutical Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,129,149.00 in company stock.

  • Percentage Held by Insiders

    0.60% of the stock of West Pharmaceutical Services is held by insiders.

  • Percentage Held by Institutions

    93.90% of the stock of West Pharmaceutical Services is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about West Pharmaceutical Services' insider trading history.
Receive WST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for West Pharmaceutical Services and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Stock News Headlines

West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
West Pharmaceutical Services (WST)
West Pharmaceutical lifts guidance on HVP-driven surge
See More Headlines

WST Stock Analysis - Frequently Asked Questions

West Pharmaceutical Services' stock was trading at $275.53 at the beginning of the year. Since then, WST shares have increased by 19.3% and is now trading at $328.6060.

West Pharmaceutical Services, Inc. (NYSE:WST) announced its earnings results on Thursday, July, 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. The business's quarterly revenue was up 13.8% compared to the same quarter last year.
Read the conference call transcript
.

West Pharmaceutical Services' Board of Directors initiated a share repurchase program on Tuesday, February 17th 2026, which permits the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 5.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its shares are undervalued.

West Pharmaceutical Services subsidiaries include these companies: Drug Delivery Assets From Plastef Investissements SA, Medimop Medical Projects Ltd., The Tech Group Inc., Tech Group Europe Limited (dba West), Tech Group Grand Rapids Inc. (dba West), TGPR Holdings Limited, WD SG Pte. Ltd., and more.

West Pharmaceutical Services' top institutional investors include Seilern Investment Management Ltd (0.20%), Assenagon Asset Management S.A. (0.09%), Handelsbanken Fonder AB (0.07%) and Wasatch Advisors LP (0.03%). Insiders that own company stock include Eric Mark Green, Thomas W Hofmann, Quintin J Lai, Annette F Favorite, Bernard Birkett, Cindy Reiss-Clark, Silji Abraham, Chad Winters and Charles Witherspoon.
View institutional ownership trends
.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that West Pharmaceutical Services investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Home Depot (HD), Chevron (CVX) and Netflix (NFLX).

Company Calendar

Record date for 5/6 Dividend
4/29/2026
Ex-Dividend for 5/6 Dividend
4/29/2026
Dividend Payable
5/06/2026
Last Earnings
7/23/2026
Today
7/26/2026
Record date for 8/5 Dividend
7/29/2026
Ex-Dividend for 8/5 Dividend
7/29/2026
Dividend Payable
8/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED/DENTAL - SUPP
Sub-Industry
Health Care Supplies
Current Symbol
NYSE:WST
CIK
105770
Employees
10,800
Year Founded
1923

Price Target and Rating

High Price Target
$447.00
Low Price Target
$295.00
Potential Upside/Downside
+10.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$7.81
Trailing P/E Ratio
42.08
Forward P/E Ratio
36.80
P/E Growth
2.55
Net Income
$493.70 million
Net Margins
16.98%
Pretax Margin
20.85%
Return on Equity
20.11%
Return on Assets
14.83%

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
2.82
Quick Ratio
2.04

Sales & Book Value

Annual Sales
$3.07 billion
Price / Sales
7.55
Cash Flow
$9.75 per share
Price / Cash Flow
33.71
Book Value
$42.33 per share
Price / Book
7.76

Miscellaneous

Outstanding Shares
70,650,000
Free Float
70,224,000
Market Cap
$23.22 billion
Optionable
Optionable
Beta
1.16

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:WST) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners